Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

Bibliografski detalji
Glavni autori:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Format:	Journal article
Izdano:	Frontiers Media 2018

Slični predmeti

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
od: Sarah Westwood, i dr.
Izdano: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
od: Westwood, S, i dr.
Izdano: (2017)

New CSF biomarkers on the block
od: Charlotte E Teunissen, i dr.
Izdano: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
od: Rosha Babapour Mofrad, i dr.
Izdano: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
od: Nevado-Holgado, A, i dr.
Izdano: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
od: Eleonora M. Vromen, i dr.
Izdano: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
od: Baird, A, i dr.
Izdano: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
od: Alejo J Nevado-Holgado, i dr.
Izdano: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
od: Betty Marije Tijms, i dr.
Izdano: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
od: Yong-Jin Park, i dr.
Izdano: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
od: Sanna Hellberg, i dr.
Izdano: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
od: Teunissen, C, i dr.
Izdano: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
od: Lyduine E. Collij, i dr.
Izdano: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
od: Si Eun Kim, i dr.
Izdano: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
od: Eline A. J. Willemse, i dr.
Izdano: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
od: Stephanie J B Vos, i dr.
Izdano: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
od: Yanaika S. Hok‐A‐Hin, i dr.
Izdano: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
od: Winchester, L, i dr.
Izdano: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
od: Mark R. Battle, i dr.
Izdano: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
od: Charlotte E. Teunissen, i dr.
Izdano: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
od: Vandenberghe, R, i dr.
Izdano: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
od: Young-Sil An, i dr.
Izdano: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
od: Taesik Yun, i dr.
Izdano: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
od: Juhan Reimand, i dr.
Izdano: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
od: Westwood, S, i dr.
Izdano: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
od: Vandenberghe, R, i dr.
Izdano: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
od: Hugh G. Pemberton, i dr.
Izdano: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
od: Chan Ju Ryu
Izdano: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
od: Fiona Heeman, i dr.
Izdano: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
od: Cullen, B, i dr.
Izdano: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
od: Nevado-Holgado, A, i dr.
Izdano: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
od: Winchester, L, i dr.
Izdano: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
od: LEI Zhe, i dr.
Izdano: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
od: Milos D. Ikonomovic, i dr.
Izdano: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
od: Hiroshi Matsuda, i dr.
Izdano: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
od: Alison Louise Baird, i dr.
Izdano: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
od: Carla M. Startin, i dr.
Izdano: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
od: Laura M. Winchester, i dr.
Izdano: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
od: Wesenhagen, KEJ, i dr.
Izdano: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
od: Kirsten E. J. Wesenhagen, i dr.
Izdano: (2025-03-01)